跳至主要内容
临床试验/NL-OMON30739
NL-OMON30739尚未招募不适用

Safety and efficacy of vaccination with T cell-dependent and T cell-independent primary and recall antigens in patients with rheumatoid arthritis treated with anti TNF-* antibodies (adalimumab) or anti B cell therapy (Rituximab). - SEVRA

Academisch Medisch Centrum0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - RA diagnosed according to the revised 1987 criteria of the American College of Rheumatology (ACR) for at least 3 months
  • - Age 18-85 years
  • -Eligible for anti-TNF * or Rituximab therapy (according to the Dutch guidelines)

排除标准

  • - Pregnancy
  • - Breastfeeding
  • - Therapy within the previous 60 days with:
  • *any experimental drug
  • *alkylating agents, e.g. cyclophosphamide, chlorambucil
  • *monoclonal antibodies (including infliximab and etanercept)
  • *growth factors
  • *other cytokines
  • - A positive PPD skin test (> 4 mm induration)
  • - HIV infection
  • - History of severe allergic or anaphylactic reactions to vaccines
  • - Vaccination with KLH, Pneumovax, Meningovax, Polio or tetanus toxoid in the past 12 months
  • - Fever (orally measured > 38 °C), chronic infections or infections requiring anti-microbial therapy
  • - Manifest cardiac failure (stage III or IV according to NYHA classification)
  • - Progressive fatal disease/terminal illness

研究者

相似试验

Safety and efficacy of vaccination with T... | 临床试验